Seletracetam
From Wikipedia, the free encyclopedia
|
Seletracetam
|
|
| Systematic (IUPAC) name | |
| (2S)-2-[(4R)-4-(2,2-difluoroethenyl) -2-oxo-pyrrolidin-1-yl]butanamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C10H14F2N2O |
| Mol. mass | 232.227 |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | >90% |
| Metabolism | ? |
| Half life | 8h |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Unscheduled (US) |
| Routes | Oral |
Seletracetam is a drug of the racetam family. It is currently being developed by UCB Pharmaceuticals as an anticonvulsant drug. While similar in structure to so-called nootropic drugs, it is not expected to have cognitive enhancing properties.
[edit] See also
|
|||||

